ReviewInternational journal of molecular sciences2017
Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis.Infection · 2020Pooled it
- Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2019Pooled it
- Mind⁻Body (Baduanjin) Exercise Prescription for Chronic Obstructive Pulmonary Disease: A Systematic Review with Meta-Analysis.International journal of environmental research and public health · 2018Pooled it
- Long-Term Risk of Mortality Associated with Isolation ofInternational journal of chronic obstructive pulmonary diseasePooled it
- A study of clinical profile, sputum microbiology, and laboratory parameters of patients admitted with acute exacerbation of chronic obstructive pulmonary diseases in rural-based hospital.Journal of family medicine and primary care · 2026Article
- Automated Chronic Obstructive Pulmonary Disease Phenotyping and Control Assessment in Primary Care: Retrospective Multicenter Study Using the Seleida Model.JMIR medical informatics · 2025Article
- Risk Factors and Outcomes in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Cureus · 2025Article
- Challenges and Opportunities for the Management of COPD: A Narrative Review of Patient and Health Care Professional Perspectives.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Mucosomes as next-generation drug carriers for treating mucus-resident bacterial infections and biofilms.Scientific reports · 2025Article
- Modulation of T Cell Differentiation in Mice with COPD Combined with Lung Cancer Through Key Targets of PD-1 by Tao Hong Si Wu Tang.Applied biochemistry and biotechnology · 2024Article
- Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy.Nature communications · 2024Article
- Review
- Phenotypic heterogeneity unveils a negative correlation between antibiotic resistance and quorum sensing inFrontiers in microbiology · 2024Article
- In-hospital antibiotic use for severe chronic obstructive pulmonary disease exacerbations: a retrospective observational study.BMC pulmonary medicine · 2023Observational
- Forthcoming complications in recovered COVID-19 patients with COPD and asthma; possible therapeutic opportunities.Cell communication and signaling : CCS · 2022Review
- Decalogue for the selection of oral antibiotics for lower respiratory tract infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- The Impact of Chronic Bronchial Infection in COPD: A Proposal for Management.International journal of chronic obstructive pulmonary disease · 2022Review
- [Oral antibiotic treatment of exacerbation of COPD. Beyond COVID-19].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021Review
- Diseased lungs may hinder COVID-19 development: A possible reason for the low prevalence of COPD in COVID-19 patients.Medical hypotheses · 2021Article
- [Current microbiological aspects of community respiratory infection beyond COVID-19].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic infections are associated with exacerbation in patients with chronic obstructive pulmonary disease (COPD). The major objective of the management of these patients is the prevention and effective treatment of exacerbations. Patients that have increased sputum production, associated with purulence and worsening shortness of breath, are the ones that will benefit from antibiotic therapy. It is important to give the appropriate antibiotic therapy to prevent treatment failure, relapse, and the emergence of resistant pathogens. In some patients, systemic corticosteroids are also indicated to improve symptoms. In order to identify which patients are more likely to benefit from these therapies, clinical guidelines recommend stratifying patients based on their risk factor associated with poor outcome or recurrence. It has been identified that patients with more severe disease, recurrent infection and presence of purulent sputum are the ones that will be more likely to benefit from this therapy. Another approach related to disease prevention could be the use of prophylactic antibiotics during steady state condition. Some studies have evaluated the continuous or the intermittent use of antibiotics in order to prevent exacerbations. Due to increased bacterial resistance to antibiotics and the presence of side effects, several antibiotics have been developed to be nebulized for both treatment and prevention of acute exacerbations. There is a need to design long-term studies to evaluate these interventions in the natural history of the disease. The purpose of this publication is to review our understanding of the role of bacterial infection in patients with COPD exacerbation, the role of antibiotics, and future interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.